Science & Technology

BIOLOGY OF ALLERGY

Understanding the Biology of Allergy


Allergic diseases are driven by IgE-mediated immune signaling, a central pathway responsible for initiating and amplifying allergic inflammation.


In susceptible individuals, exposure to allergens leads to the production of IgE antibodies, which bind to immune cells in the respiratory mucosa. Activation of this IgE signaling cascade triggers the release of inflammatory mediators, resulting in the characteristic symptoms of allergic rhinitis, asthma, and other allergic respiratory conditions.


Because of its central role, the IgE pathway has long been recognized as a critical therapeutic target in the treatment of allergic disease.

SCIENCE MECHANISM

A Novel Mechanism to Modulate IgE Signaling


Egafusp is designed to modulate IgE-mediated immune signaling through a novel biological mechanism, rather than broadly suppressing the immune system of the whole body.


The molecule acts by linking two key immune regulatory receptors involved in IgE signaling, restoring natural inhibitory control over allergic immune activation. This approach represents a fundamentally different strategy for addressing allergic inflammation and has been regarded as a breakthrough concept among prominent immunologists around the world.


By targeting immune regulation at the signaling level, Egafusp aims to interrupt allergic responses at their source, enhancing effectiveness in treating allergic disorders.


GENERATION

Second-Generation Fusion Protein Engineering


Egafusp represents a second-generation fusion protein, developed through extensive molecular engineering and optimization.


Compared with earlier fusion protein designs, this next-generation molecule has been engineered to:


  • Enhance therapeutic effectiveness
  • Reduce the risk of unintended allergic or immune-mediated reactions
  • Improve molecular stability and manufacturability
  • Increase overall production efficiency

These advances reflect a significant evolution in fusion protein design, supporting both clinical performance and scalable development.




MILESTONE

Advancing Inhaled Biologic Therapy


A major milestone in the development of Egafusp has been the successful formulation of the molecule as a stable dry-powder protein.


This innovation enables:


Intranasal delivery

Intranasal delivery for allergic rhinitis

Inhalation therapy

Inhalation therapy for allergic asthma and other respiratory allergic diseases



Why Egafusp Is Different ?


Biologic medicines have become increasingly important for treating allergic diseases, especially for patients whose symptoms are not well controlled by standard treatments like antihistamines, steroid sprays, or other allergy medications. These biologics can be very effective—but today, they also come with major limitations.


Most existing biologic allergy treatments must be given by injection, often in a doctor’s office. They usually need to be stored in a refrigerator and cannot be used as nasal sprays or inhalers. This makes treatment inconvenient, limits flexibility, and can be burdensome for patients who need long-term care.


Egafusp is designed to change that.


Egafusp is a biologic therapy formulated as a stable dry powder that can be delivered directly to the nose or lungs—right where allergic inflammation begins. It is easy for patients to self-administer, without injections or clinic visits. Unlike traditional biologics, Egafusp can be stored at room temperature for over a year, allowing patients to carry and use their medication without worrying about refrigeration or loss of activity.


By combining the effectiveness of biologic therapy with the convenience of nasal and inhaled delivery, Egafusp aims to remove key barriers to treatment and offer patients a safer, more practical, and more flexible option for managing allergic diseases.